Two-Thirds of Severe COVID-19 Cases Improved on Experimental Drug

Sciences Inc.’s experimental drug for patients with severe COVID-19 infections showed promise in an early analysis, raising tentative hope that the first treatment for the novel virus may be on the horizon.

The report published in the New England Journal of Medicine tracked 53 people in the U.S., Europe and Canada who needed respiratory support, with about half receiving mechanical ventilation and four on a heart-lung by-pass machine. Eight additional patients were left out of the analysis: one due to a dosing error and seven because no information was available on how they fared.

All received remdesivir for up to 10 days on a compassionate use basis, a program that allows people to use unapproved medicines when no other treatment options are available. Over 18 days, 68% of the patients improved, with 17 of the 30 patients on mechanical ventilation being able to get off the breathing device. Almost half of the patients studied were ultimately discharged, while 13% died. Mortality was highest among those who were on a ventilator, with 18% of them dying.

“We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said lead author Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles, in a statement from Gilead. The Foster City, California-based company provided the medication and also helped analyze the results.

Some scientists have expressed skepticism with regard to the results.

“The data from this paper are almost uninterpretable,” Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said in an emailed statement. “There is some evidence suggesting efficacy, but we simply do not know what would have happened to these patients had they not been given the drug.”

Several large scale clinical trials are underway to evaluate the benefit of remdesivir for COVID-19, the disease caused by the novel coronavirus that has infected more than 1.65 million people worldwide and killed 100,000. One that was conducted in China could report results this month. Another, sponsored by the U.S. National Institutes of Health, has enrolled patients rapidly as the virus spread throughout the U.S. It could also report results in the coming weeks. Gilead itself is sponsoring an additional two trials.

‘Answers Are Needed’

“In studying remdesivir, the question is not just whether it is safe and effective against COVID-19, but in which patients it shows activity, how long should they receive treatment and at what stage of their disease would treatment be most beneficial,” said Daniel O’Day, Gilead’s chairman and chief executive officer. “Many answers are needed, which is why we need multiple types of studies involving many types of patients.”

Some of these answers will emerge in the coming weeks with the release of initial data from the various clinical trials, O’Day said Friday in an open letter sent via email.

There are currently no treatments proven to work specifically against the coronavirus infection. Gilead has provided the medicine to more than 1,800 patients on a compassionate use basis.

Cheap to Make

If it’s shown to be safe and effective for treating COVID-19, the medication is estimated to cost about $9 a treatment to make, said Andrew Hill, a senior visiting research fellow in the pharmacology department at Liverpool University, and colleagues in a study Friday.

As an intravenous infusion, there would be additional costs to administer remdesivir, which are likely to exceed the estimated manufacturing, the authors said.

Results of controlled studies of remdesivir are highly anticipated because they will be some of the first rigorous large-scale studies completed on potential anti-coronavirus drugs.

President Donald Trump and others have touted the potential of hydroxychloroquine, an old malaria and lupus drug, for treating COVID-19. But that drug hasn’t yet been carefully studied in a large trial to see if it prevents severe complications. Most of the excitement stems from relentless social media promotion of a tiny French study whose methodology has been heavily criticized by many U.S. medical experts.

Remdesivir, a broad-spectrum antiviral, is viewed by researchers and doctors as one of the most promising agents against COVID-19 to enter human trials to date. In lab studies conducted prior to the COVID-19 outbreak on numerous compounds, researchers at the University of North Carolina and Vanderbilt University found the drug had potent activity against against a wide variety of coronaviruses similar to the new coronavirus.

Tested for Ebola

Because it had already been tested in patients with Ebola, where it was shown to be safe but ineffective, researchers were able to quickly begin studying it human trials when the COVID-19 pandemic hit.

About one in four patients on the medicine experienced severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% showed signs of liver damage on laboratory tests. Four patients had to stop receiving infusions of the drug entirely.

Remdesivir was considered to be the most promising therapeutic candidate based on its broad antiviral spectrum, and existing data based on human and animal studies, a World Health Organization panel said in January. The medication was developed initially for Ebola and studied in patients in Eastern Congo.

If it works well, one issue will be whether there is enough of a supply of the drug, especially if the epidemic is still raging. Gilead has been working all-out to bolster supply of the hard-to-make medicine. It said earlier this month that it hopes to to have 500,000 treatment courses by October, and more than 1 million by year-end. Production time has also been accelerated to six months from one year.

via newsmax

9 comments

  1. We can’t accept the nickle and dime treatment offered by hydroxychloroquine, we MUST develop an entirely new medicine which gets us into the “sky’s the limit” cost potential. The first thing that has to be done is to convince everyone that HCQ is bogus-all the proof you need is that Trump recommended it. They talk about a tiny study done in France where the results were OK, but not scientifically based. They would rather not discuss the hundreds of successful uses the world over. It sounds like the new medicine will kill you if it don’t cure you. but it’s better because it’s being properly tested. We’ll know how great it is in two years, after the testing is complete. At that time, it will be acceptable if it kills those it doesn’t cure.

    1. You DEFINITELY don’t know what you are talking about. And that’s a FACT. I definitely would ask to be put on it if I started showing symptoms of it. And they have also found out Dr. Fauci & Dr. Birx would definitely keep EVERYTHING shut down until after the Presidential election if they were in charge. They are NOT in this to help WE THE PEOPLE. Go read all about them.

      1. You got that right, they like the power and recognition they are getting and want to keep it going or go back to thier boring lives and being unknown!!

  2. Big Ed you are a TDS HATRED fool, TRUMP is telling the truth about HCQ and your TRUMP DERANGED mush brain will get you killed if you were to resist it. A Democrat congresswoman took it and lived she praised TRUMP for mentioning it or she would never had known about it!!
    Wake up dude you are living in a world of lies and if you continue to listen to the lamestream media you will never know the truth!!! I am 71 with type 2 diabetes and I would jump at the chance to get HCQ if nothing else was working!! People like you are dividing the country not TRUMP, your hatred is consuming you!!!

  3. Gilead is desperate to recover costs of a useless drug previously developed for another virus. These minimal result of 31% improvement should be compared to 69% failure.

Leave a Reply

Your email address will not be published. Required fields are marked *

*